Navigation Links
International team reveals first prognosticator of survival in aggressive cancer
Date:9/3/2008

(Philadelphia, PA September 4, 2008) The tumor suppressor gene pRb2/p130 may provide the first independent prognostic biomarker in cases of soft tissue sarcoma (STS), according to an international collaboration of researchers, including scientists at the Sbarro Institute for Cancer Research and Molecular Medicine at the College of Science and Technology at Temple University in Philadelphia, PA, the Department of Human Pathology and Oncology, University of Siena and the Center of Oncological Research of Mercogliano (CROM) in Avellino, Italy.

The research appears in the latest issue of Clinical Cancer Research (www.aacrjournals.org).

The findings show that a reduction in the expression of pRb2/p130 can mean a higher risk of recurrence and death from STSs. The gene pRb2/p130, a member of the retinoblastoma family of genes, regulates a portion of the cell cycle.

Clinicians have long sought a prognostic test for the disease, which can be highly aggressive and unpredictable, making it difficult to determine the most beneficial course of chemotherapy and/or radiation treatments following surgery.

A prognostic indicator will help doctors determine which patients have a higher risk of recurrence of the disease and who might benefit from a more aggressive adjuvant therapy.

In the study, researchers examined specimens taken from 41 patients with STS. In a subset of 31 cases of nonmetastatic cancers, they found a direct relationship between pRb2/p130 expression and the clinical outcome of patients.

"We found that pRb2/p130 expression was lost or decreased and significantly correlated with recurrence of disease and poor survival rates in the subset of patients with nonmetastatic tumors," said Valeria Masciullo, M.D., Ph.D., lead author of the study.

"A prognostic test could define the natural history of STSs, while also helping to identify possible targets for new kinds of therapies," said Antonio Giordano, M.D., Ph.D., the Director of the Sbarro Institute, Professor of Molecular Biology at the College of Science and Technology at Temple University in Philadelphia, PA and Full Professor of Pathological Anatomy and Histology of the University of Siena.

The researchers noted that the reliability of pRb2/p130 as a potential marker in the clinical routine assessment and management of patients with STS deserves to be further evaluated in long-term follow-up studies on a larger number of cases.


'/>"/>

Contact: Ilene Raymond Rush
irush@shro.org
215-635-5162
Sbarro Health Research Organization
Source:Eurekalert

Related biology news :

1. [video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.nets 3-Minute Press Show
2. NYU Langone Medical Centers tip sheet to the International Conference on Alzheimers Disease 2008
3. International conference to release new findings on smell and taste
4. International team identifies 21 new genetic risk factors for Crohns disease
5. 2008 ASABE Annual International Meeting
6. The 12th International Behavioral Ecology Congress held at Cornell University, Aug. 10-14
7. Biotechnology key to developing sustainable industries says international panel
8. BBVA Foundation international study on attitudes to stem cell research
9. International symposium explores fire suppression economics
10. International workshop to address capacity building for rainforest leaders
11. Great Ape Trust to gather internationally recognized scientists for Decade of the Mind III
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology: